Vision & Mission

The Pediatric Praziquantel Consortium is an international partnership that aims to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children. The neglected tropical disease affects 258 million people worldwide, including 28 million preschool-age children that are currently lacking adequate treatment. The Consortium operates on a not-for-profit basis.

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers. 

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

To accomplish its mission:

  • The Consortium combines some of the best science and most experienced public and private partners to develop and provide a new pediatric formulation of praziquantel to treat schistosomiasis. Read more
  • The Consortium operates through an innovative approach that engages new partners as needed. Beyond the partners contributing expertise and resources, the Consortium pro-actively promotes dialogue at all stakeholder levels and consults international academics, experts from endemic countries, funding agencies, the WHO and non-governmental organizations. Read more 
  • The pediatric formulation developed by the Consortium is a small, orally dispersible tablet with an acceptable taste. It should also withstand the challenges presented by a tropical climate. Read more
  • The clinical program comprises of a full phase I-III development program, set up in line with EMA recommendations for pediatric development. It has been designed with the support of regulatory authorities and a panel of international experts, including clinicians from endemic countries. Read more
  • The Consortium, in case of a successful outcome of the clinical program, aims to submit the Marketing Authorization Application in 2021 to have the product approved in 2022. In parallel, the Marketing Authorization Application shall be submitted in Brazil (provided that no separate Phase III trial in Brazil is needed). In case of product approval in 2022, the Consortium can start rolling out the Access phase in 2022.
  • Once approved, the product will not be donated but made available on a not-for-profit basis. The rationale behind this is that the Consortium partners do not consider donation of PZQ-ODT a durable health solution, and are exploring alternative business models, including local manufacturing. Together with relevant stakeholders, we will examine ways of providing access to the new pediatric formulation in an affordable and sustainable manner.